4D Molecular Therapeutics, Inc.
FDMTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframe4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic. The company carries a $574.5M market cap, placing it firmly in the small-cap category. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Market Cap
$574.5M
Beta
2.69
P/E (TTM)
—
P/E (Fwd)
-2.95
EPS (TTM)
$-2.61
EPS (Fwd)
$-3.73
ROE
-34.9%
ROA
-21.4%
Cash
$390.9M
Total Debt
$20.5M
Free CF
-$69.4M
52W Change
160.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $390.9M in cash comfortably exceeding the $20.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$69.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -34.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $3.1M (2022) to $85.2M (2025), reflecting a 2623% increase over the period.
4D Molecular Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence 4D Molecular Therapeutics, Inc.'s trajectory.